U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241546) titled 'Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma' on Nov. 17.
Brief Summary: The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Asthma
Intervention:
DRUG: ARO-RAGE
Inhalation of nebulized solution
DRUG: Placebo
Calculated volume to match active treatment by inhalation of nebulized solution
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Arrowhead Pharmaceuticals
Disclaimer: Curated by HT Syndication....